Публикации\НИЛ Индустриальная биофармацевтика / НИЛ Биомедицинские технологии --- (CAR-T терапия) - Казанский (Приволжский) федеральный университет
Статьи

37. Quartile Q1. Impact factor = 18.962

Dong Y, Tu Y, Liu Y, Jiang M, Bulatov E, Yuan Y, Wang J. Perivascular nanocarrier aggregation as a drug reservoir augments tumor drug delivery and treatment efficacy. // Nano Today. 2023 Dec 1;53:102004.
DOI: 10.1016/j.nantod.2023.102004​

===================================================================================

36.  Quartile Q2. Impact factor = 2.3

Chasov V, Davletshin D, Gilyazova E, Mirgayazova R, Kudriaeva A, Khadiullina R, Yuan Y, Bulatov E. Anticancer therapeutic strategies for targeting mutant p53-Y220C. // The Journal of Biomedical Research. 2023 Nov 1;37:1-1.
DOI: 10.7555/JBR.37.20230093

===================================================================================

35. Quartile Q3. Impact factor = 0.334

Valiullina AK, Zmievskaya EA, Ganeeva IA, Zhuravleva MN, Garanina EE, Rizvanov AA, Petukhov AV, Bulatov ER. Сytotoxic effect of CAR-T cells against modified MCF-7 breast cancer cell line.  // Molecular Biology Research Communications. 2023;12(4):139.
DOI: 10.22099/mbrc.2023.47125.1820

==================================================================================
34. Quartile Q1. Impact factor = 4.757

Valiullina AK, Zmievskaya EA, Ganeeva IA, Zhuravleva MN, Garanina EE, Rizvanov AA, Petukhov AV, Bulatov ER. Evaluation of CAR-T Cells' Cytotoxicity against Modified Solid Tumor Cell Lines. // Biomedicines. 2023 Feb 19;11(2):626.
DOI: 10.3390/biomedicines11020626

===================================================================================
33. Quartile Q4 (российский журнал)

К.А. Левчук, А.А. Голдаева, Е.А. Столярова, П.А. Матейкович, А.Х. Валиуллина, Э.Р. Булатов, А.В. Петухов, А.А. Дакс, Н.А. Барлев, Е.В. Байдюк, Я.Г. Торопова / Классические и активирующие химерные антигенные рецепторы PD-1 как элемент мультитаргетного подхода в лечении гематологических и солидных новообразований // Клиническая онкогематология. 2023;16(3):268–79.
DOI: 10.21320/2500-2139-2023-16-3-268-279


===================================================================================

32. Quartile Q1. Impact factor = 4.6

Diana Mironova, Egor Makarov, Islamiya Bilyukova, Kevser Akyol, Elsa Sultanova, Vladimir Evtugyn, Damir Davletshin, Elvina Gilyazova, Emil Bulatov, Vladimir Burilov, Svetlana Solovieva, Igor Antipin / Aggregation, Cytotoxicity and DNA Binding in a Series of Calix [4] arene Amphiphile Containing Aminotriazole Groups // Pharmaceuticals. 2023 May 5;16(5):699.
https://doi.org/10.3390/ph16050699

===================================================================================

31. Quartile Q1. Impact factor = 6.208

Vildan Sultanaev, Luidmila Yakimova, Anastasia Nazarova, Olga Mostovaya, Igor Sedov, Damir Davletshin, Elvina Gilyazova, Emil Bulatov, Zhang-Ting Li, Dan-Wei Zhang, Ivan Stoikov / Decasubstituted Pillar [5] arene Derivatives Containing L-Tryptophan and L-Phenylalanine Residues: Non-Covalent Binding and Release of Fluorescein from Nanoparticles // International Journal of Molecular Sciences. 2023 Apr 22;24(9):7700.
https://doi.org/10.3390/ijms24097700

===================================================================================

30. Quartile Q4 (российский журнал)

Ю. А. Топчу, М. В. Тихомирова, Э. Р. Булатов, З. И. Абрамова, Я. А. Бумбер / Нокаут гистоновой метилтрансферазы NSD1 приводит к снижению пролиферации и увеличению чувствительности к цисплатину клеток плоскоклеточного рака гортани // Сибирский онкологический журнал. 2023;22(2):76-84.
https://doi.org/10.21294/1814-4861-2023-22-2-76-84

===================================================================================

29. Quartile Q2. Impact factor = 3.253

​Raniya Khadiullina, Regina Mirgayazova, Damir Davletshin, Elvina Khusainova, Vitaly Chasov, Emil Bulatov*Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry // Life. 2022 Dec 22;13(1):31.
https://doi.org/10.3390/life13010031

===================================================================================

28. Quartile Q2. Impact factor = 5.046

Irina Ganeeva, Ekaterina Zmievskaya, Aygul Valiullina, Anna Kudriaeva, Regina Miftakhova, Alexey Rybalov, Emil Bulatov*Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies // Bioengineering. 2022 Dec 15;9(12):808.
https://doi.org/10.3390/bioengineering9120808

===================================================================================

27. Quartile Q1. Impact factor = 6.633

Anastasia Nazarova, Luidmila Yakimova, Olga Mostovaya, Tatiana Kulikova, Olga Mikhailova, Gennady Evtugyn, Irina Ganeeva, Emil Bulatov, Ivan Stoikov / Encapsulation of the quercetin with interpolyelectrolyte complex based on pillar [5] arenes // Journal of Molecular Liquids. 2022 Dec 15;368:120807. 
https://doi.org/10.1016/j.molliq.2022.120807

===================================================================================

26.Quartile Q1. Impact factor = 6.102

Georgiy Korenev, Sergey Yakukhnov, Anastasia Druk, Anastasia Golovina, Vitaly Chasov, Regina Mirgayazova, Roman Ivanov, Emil Bulatov* / USP7 inhibitors in cancer immunotherapy: current status and perspective // Cancers. 2022 Nov 10;14(22):5539.
https://doi.org/10.3390/cancers14225539

===================================================================================

25.Quartile Q1. Impact factor = 6.0

Joseph R Stephenson Clarke, Leon R Douglas, Patrick J Duriez, Dimitrios-Ilias Balourdas, Andreas C Joerger, Raniya Khadiullina, Emil Bulatov, Matthias GJ Baud / Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C // ACS Pharmacology & Translational Science. 2022 Oct 11;5(11):1169-80.
https://doi.org/10.1021/acsptsci.2c00164

         


===================================================================================
24. Quartile Q1. Impact factor = 8.786.

Kaminskiy Y, Kuznetsova V, Kudriaeva A, Zmievskaya E, Bulatov E.* / Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion. // Frontiers in Immunology. 2022 Oct 4;13:971045.
https://doi.org/10.3389/fimmu.2022.971045

===================================================================================
23. Quartile Q4 (российский журнал)

Валиуллина А.Х., Змиевская Е.А., Рахматуллина А.Р., Журавлева М.Н., Гаранина Е.Е., Мифтахова Р.Р., Петухов А.В., Ризванов А.А., Булатов Э.Р.* / Оценка цитотоксичности CAR-T-клеток против модели карциномы предстательной железы // Учен. зап. Казан. ун-та. Сер. Естеств. науки. – 2022. – Т. 164, кн. 2. – С. 212–230.
doi: 10.26907/2542-064X.2022.2.212-230

===================================================================================

22. Quartile Q1. Impact factor = 6.102.

Aleksei Titov, Yaroslav Kaminskiy, Irina Ganeeva, Ekaterina Zmievskaya, Aygul Valiullina, Aygul Rakhmatullina, Alexey Petukhov, Regina Miftakhova, Albert Rizvanov, Emil Bulatov* / 
Knowns and Unknowns about CAR-T Cell Dysfunction // Cancers. 2022 Feb 21;14(4):1078.
https://doi.org/10.3390/cancers14041078

===================================================================================

21. Quartile Q1. Impact factor = 6.102.
Aleksei Titov, Ekaterina Zmievskaya, Irina Ganeeva, Aygul Valiullina, Alexey Petukhov, Aygul Rakhmatullina, Regina Miftakhova, Michael Fainshtein, Albert Rizvanov, and Emil Bulatov* / Adoptive Immunotherapy beyond CAR T-Cells // Cancers (Basel). 2021 Feb; 13(4): 743.
https://doi.org/10.3390/cancers13040743

===================================================================================

20. Quartile Q1. Impact Factor = 6.08.
Zmievskaya, E.; Valiullina, A.; Ganeeva, I.; Petukhov, A.; Rizvanov, A.; Bulatov, E. */ Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections // Biomedicines, (2021), 9(1), p.59.
https://doi.org/10.3390/biomedicines9010059

===================================================================================

19. Quartile Q1. Impact Factor = 6.429.
Chasov V, Zaripov M, Mirgayazova R, Khadiullina R., Zmievskaya E., Ganeeva I., Valiullina A., Rizvanov A., Bulatov E.* / Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies // Frontiers in Immunology, (2021). Vol.12, Is. - Art. №707734.
https://doi.org/10.3389/fimmu.2021.707734

===================================================================================

18. Quartile Q1. Impact Factor = 4.848
Vitaly Chasov, Regina Mirgayazova, Ekaterina Zmievskaya, Raniya Khadiullina, Aygul Valiullina, Joseph Stephenson Clarke,  Albert Rizvanov,  Matthias G. Baud* and  Emil Bulatov* /
Key Players In The Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy //
Front. Oncol., (2020), 10:1460
https://doi.org/10.3389/fonc.2020.01460

===================================================================================

17. Quartile Q1. Impact Factor = 3.331
Mirgayazova, R., Khadiullina,R., Chasov, V., Mingaleeva,R., Miftakhova, R., Rizvanov, A., Bulatov, E*. / Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option? // Genes, 2020, 11(6), p.704.
https://doi.org/10.3390/genes11060704

===================================================================================

16. Quartile Q4 (российский журнал)
Д.В. Зайцев, Е.К. Зайкова, А.С. Головкин, Э.Р. Булатов, А.Х. Валиуллина, Р.М. Миргаязова, А.А. Дакс, А.Ю. Зарицкий, А.В. Петухов. / Гранулоцитарно-макрофагальный колониестимулирующий фактор и технология CAR-T при солидных опухолях в эксперименте.
Клиническая онкогематология. 2020;13(2):115–22
http://bloodjournal.ru/granulotsitarno-makrofagalnyj-koloniestimuliruyushhij-faktor-i-tehnologiya-car-t-pri-solidnyh-opuholyah-v-eksperimente/

===================================================================================

15. Quartile Q1. Impact Factor = 6.162
Aleksei Titov, Aygul Valiullina, Ekaterina Zmievskaya, Ekaterina Zaykova, Alexey Petukhov, Regina Miftakhova, Emil Bulatov* and Albert Rizvanov / Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment // Cancers, 2020, 12, 125.
https://doi.org/10.3390/cancers12010125

===================================================================================

14. Quartile Q4. CiteScore = 1.4
Regina Mirgayazova, Raniya Khadiullina, Rimma Mingaleeva, Vitaly Chasov, Marina Gomzikova, Ekaterina Garanina, Albert Rizvanov, Emil Bulatov* / Novel Isatin-based activator of p53 trans­criptional functions in tumor cells // Molecular Biology Research Communications 2019;8(3):119-128 
CiteScore = 1. DOI: 10.22099/mbrc.2019.34179.1419

===================================================================================
13. Quartile Q2. Impact Factor = 4.114

Emil Bulatov, Regina Sayarova, Rimma Mingaleeva, Regina Miftakhova, Marina Gomzikova, ​Yuri Ignatyev, Alexey Petukhov, Pavel Davidovich, Albert Rizvanov, Nickolai Barlev / Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors // ​Cell Death Discovery, 4: 103 (2018) https://doi.org/10.1038/s41420-018-0120-z

===================================================================================

12. Quartile Q1. Impact Factor = 6.187
Aleksei Titov, Alexey Petukhov, Alena Staliarova, Dmitriy Motorin, Emil Bulatov, Oleg Shuvalov, Surinder M. Soond, Mauro Piacentini, Gerry Melino, Andrey Zaritskey & Nickolai A. Barlev /
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites // 
Cell Death & Disease, 9: 897 (2018) 
https://doi.org/10.1038/s41419-018-0918-x

===================================================================================

11. Quartile Q2. Impact Factor = 2.664  
Emil Bulatov, Aygul Valiullina, Regina Sayarova, Albert Rizvanov /
Promising new therapeutic targets for regulation of inflammation and immunity:
RING-type E3 ubiquitin ligases
 //
Immunology Letters (2018) vol. 202, pp. 44-51
https://doi.org/10.1016/j.imlet.2018.08.001


===================================================================================

10. Quartile Q1. Impact Factor  = 4.439
Emil Bulatov, Almaz Zagidullin, Aygul Valiullina, Regina Sayarova, Albert Rizvanov /
Small molecule modulators of RING-type E3 ligases: MDM and Cullin families as targets // 
Frontiers in Pharmacology. (2018) 9:450.
https://doi.org/10.3389/fphar.2018.00450


===================================================================================

9. Book Chapter
Emil Bulatov. E3 Ubiquitin Ligases as Targets for Small Molecule Drug Discovery: Focusing on the Cullin Ring Family. Chapter in: Ubiquitin Proteasome System: A Review and Directions for Research. (2018) Nova Science Publishers.  
https://novapublishers.com/shop/ubiquitin-proteasome-system-a-review-and-directions-for-research/

===================================================================================

8. Quartile Q1. Impact Factor  = 4.439
G. Vafina, E. Zainutdinova, E. Bulatov, M.N. Filimonova /
Endonuclease from Gram-Negative Bacteria Serratia marcescens Is as Effective as Pulmozyme in the Hydrolysis of DNA in Sputum // 
Frontiers in Pharmacology. (2018) Vol. 9. - Is. 114. - PP. 1-8. 
https://doi.org/10.3389/fphar.2018.00114

  

​​